Contact
Shahid AhmadOntario Bioscience Innovation Organization (OBIO)
416-848-6839 x 104
shahidahmad@obio.ca
Structuring the Deal:
What’s “Market” in Early Stage Financing
Are you a health technology company raising early rounds of financing?
OBIO invites you to learn from leading industry experts Vanessa Grant and Michelle McBane who will discuss both cutting edge and conventional approaches to the early stage financing process, as well as all the latest bells and whistles. Offered in-person (limited seating! Priority will be given to OBIO members) and via webinar.
- Learn about the latest alternative investment vehicles (SAFEs / KISS contracts) and walk through real world examples.
- Understand common term sheet pitfalls and what to watch out for, including bad terms for entrepreneurs.
- Delve into term sheets & contracts at different stages of raising capital, with a focus on Angel/VC early stage investments.
Vanessa Grant, Partner at Norton Rose Fulbright
Vanessa practises business law in their Toronto office. Her practice focuses on mergers and acquisitions, corporate finance and corporate governance for public and private corporations, including private equity and venture capital. She also provides ongoing general corporate and commercial legal advice to a number of clients. She has worked with several national and international clients in various industries, with a particular focus on technology companies, life sciences companies, and REITs. Vanessa is currently the co-director of the Osgoode Hall part-time LLM in business law, and teaches corporate finance for the program.
Michelle McBane, Investment Director at MaRS IAF
Michelle is passionate about working with amazing technology entrepreneurs. As a Director at the MaRS Investment Accelerator Fund, she leads investments in early-stage technology companies. Michelle is a skilled business professional with over 25 years of combined operational and venture capital experience. Her background includes 15 years of venture capital investing early-stage companies as well as sales and marketing roles in both engineering and scientific industries. Since 2010, she has led over 20 investments in her role at IAF.